6976 Share Price Performance
NT$13.15
-8.75 (-39.95%)
Price NT$13.15
Share Pricen/a
Acepodia, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6976 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Acepodia, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -1.13
- 61.13%
- -217,792.36%
- 0%
About 6976
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 that is in phase 1 clinical trial. Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. The company is based in Grand Cayman, the Cayman Islands.
